The Net Margin of Gilead Sciences, Inc. (GILD) is
28.90%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2025-12-31 |
28.90%
|
| 2024-12-31 |
1.67%
|
| 2023-12-31 |
20.89%
|
| 2022-12-31 |
16.83%
|
| 2021-12-31 |
22.80%
|
| 2020-12-31 |
0.50%
|
| 2019-12-31 |
23.99%
|
| 2018-12-31 |
24.65%
|
| 2017-12-31 |
17.73%
|
| 2016-12-31 |
44.43%
|
| Ticker |
Name |
Value |
|
INCY
|
Incyte Corp
|
25.03%
|
|
IONS
|
Ionis Pharmaceuticals, Inc.
|
-40.41%
|
|
SRPT
|
Sarepta Therapeutics, Inc.
|
-32.45%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
BHVN
|
Biohaven Ltd.
|
-1205.09%
|
|
FATE
|
Fate Therapeutics Inc
|
-2051.08%
|
|
TPTX
|
Turning Point Therapeutics Inc
|
-767.30%
|
|
XLRN
|
Acceleron Pharma Inc
|
-179.45%
|
|
APLS
|
Apellis Pharmaceuticals, Inc.
|
2.23%
|
|
BNTX
|
Biontech SE
|
-39.59%
|
|
SGEN
|
Seagen Inc
|
-31.10%
|
|
TGTX
|
TG Therapeutics, Inc.
|
72.56%
|
|
ALKS
|
Alkermes Plc
|
16.37%
|
|
EBS
|
Emergent BioSolutions Inc.
|
7.08%
|
|
CRSP
|
CRISPR Therapeutics AG
|
-16569.77%
|
|
MRTX
|
Mirati Therapeutics Inc
|
-5955.55%
|
|
NTLA
|
Intellia Therapeutics, Inc.
|
-609.85%
|
|
BPMC
|
Blueprint Medicines Corp
|
-13.19%
|
|
HALO
|
Halozyme Therapeutics, Inc.
|
22.69%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|
|
ASND
|
Ascendis Pharma A/S
|
-31.67%
|
|
ALNY
|
Alnylam Pharmaceuticals, Inc.
|
8.45%
|
|
CVAC
|
CureVac NV
|
30.30%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
UTHR
|
United Therapeutics Corporation
|
41.94%
|
|
ALLO
|
Allogene Therapeutics, Inc.
|
-1170863.70%
|